# HUMAN MYELOMA ANALOGUES FOR MAKING MONOCLONAL ANTIBODIES

> **NIH NIH R01** · ROGER WILLIAMS HOSPITAL · 1987 · $75,402

## Abstract

Myeloma analogs constructed by somatic cell hybridization will be selected
for important characteristics that will enable them to be used for the
routine production of human monoclonal antibodies.  These characteristics
include the easy growth and high cloning efficiency of the primary cell
line, high fusion efficiency, easy growth, and high cloning efficiency of
the subsequent hybrids and continuous and stable secretion of antibody by
these hybrids.  New cell lines will be constructed if the presently
available cell lines do not meet the standards set by the laboratory.  In
addition, myeloma analogs will be selected for ouabain-resistant mutants
for fusion with other cell lines to construct new myeloma analogs or for
fusion with transformed B lymphocytes secreting antibody.  Myeloma analogs
meeting the above criteria will be further selected for nonsecreting
variants utilizing well-established methods.  In order to obtain antibody
secreting hybrids or predetermined specificity, methods will be developed
to select, activate, and expand populations of B cells for fusion and/or
transformation with EBV and subsequent fusion with myeloma analogs.  These
experiments will start with a system utilizing soluble antigen (tetanus
toxoid) and proceed to in vitro secondary immunization utilizing malignant
cells or soluble antigen bound to cell surface membranes.  The influence of
populations of lymphoid cells which may affect the degree of in vitro
immunization will be studied.  The conditions under which these
immunizations are best obtained will be determined.  The final stage will
involve the production of human monoclonal antibodies to colon carcinoma,
melanoma, and acute myelogenous leukemia.  (2)

## Key facts

- **NIH application ID:** 3176891
- **Project number:** 5R01CA038687-03
- **Recipient organization:** ROGER WILLIAMS HOSPITAL
- **Principal Investigator:** MARSHALL R POSNER
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1987
- **Award amount:** $75,402
- **Award type:** 5
- **Project period:** 1985-09-30 → 1989-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3176891

## Citation

> US National Institutes of Health, RePORTER application 3176891, HUMAN MYELOMA ANALOGUES FOR MAKING MONOCLONAL ANTIBODIES (5R01CA038687-03). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3176891. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*